Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Research & Development: 2014-2024

Historic Research & Development for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to $127.4 million.

  • Voyager Therapeutics' Research & Development rose 18.60% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.3 million, marking a year-over-year increase of 14.26%. This contributed to the annual value of $127.4 million for FY2024, which is 38.19% up from last year.
  • Voyager Therapeutics' Research & Development amounted to $127.4 million in FY2024, which was up 38.19% from $92.2 million recorded in FY2023.
  • Voyager Therapeutics' 5-year Research & Development high stood at $127.4 million for FY2024, and its period low was $60.8 million during FY2022.
  • Over the past 3 years, Voyager Therapeutics' median Research & Development value was $92.2 million (recorded in 2023), while the average stood at $93.4 million.
  • Per our database at Business Quant, Voyager Therapeutics' Research & Development plummeted by 32.15% in 2021 and then soared by 51.69% in 2023.
  • Yearly analysis of 5 years shows Voyager Therapeutics' Research & Development stood at $108.8 million in 2020, then crashed by 32.15% to $73.8 million in 2021, then dropped by 17.65% to $60.8 million in 2022, then soared by 51.69% to $92.2 million in 2023, then surged by 38.19% to $127.4 million in 2024.